254750-81-7

Basic information

• Product Name: (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester
• Synonyms: (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester
• CAS NO: 254750-81-7
• Molecular Weight: 424.393
• Mol File: 254750-81-7.mol

Chemical Properties

• CAS DataBase Reference: (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester(254750-81-7)
• EPA Substance Registry System: (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester(254750-81-7)

Safety Data

• Hazardous Substances Data: 254750-81-7(Hazardous Substances Data)

Upstream product

• 3057-74-7 L-Asp(t-Bu) 
• 254751-09-2 (S)-tert-butyl 3-(((benzyloxy)carbonyl)amino)-4-oxo-5-(2,3,5,6-tetrafluoro phenoxy)pentanoate 
• 254750-84-0 tert-butyl (3S)-3-(benzyloxycarbonylamino)-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate 
• 769-39-1 2,3,5,6-tetraflourophenol 
• 153088-76-7 (S)-3-benzyloxycarbonylamino-5-bromo-4-oxo-pentanoic acid tert-butyl ester 
• 5545-52-8 Z-D(tBu)-OH 
• 3408-50-2 [(N-benzyloxycarbonyl)-L-alaninyl]-L-aspartic acid [beta]-tert-butyl ester 
• 868565-57-5 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 
• 868565-55-3 (3S)-3-[(N-benzyloxycarbonyl)-L-alaninyl]amino-5-bromo-4-oxopentanoic acid tert-butyl ester 
• 868565-58-6 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 

Downstream Products

• 254750-83-9 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 
• 254750-02-2 Emricasan 

Relevant articles and documents

LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR

A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.

METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE

Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions

First-in-class pan caspase inhibitor developed for the treatment of liver disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.